Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Salivary Gland Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Head and Neck Cancer (560
)
Thyroid Gland Carcinoma (359
)
Squamous Cell Carcinoma of Head and Neck (290
)
Nasopharyngeal Carcinoma (59
)
Oral Cancer (53
)
Oropharyngeal Cancer (23
)
Maxillary Sinus Carcinoma (6
)
Tongue Carcinoma (5
)
Head and Neck Cancer (560
)
Thyroid Gland Carcinoma (359
)
Squamous Cell Carcinoma of Head and Neck (290
)
Nasopharyngeal Carcinoma (59
)
Oral Cancer (53
)
Oropharyngeal Cancer (23
)
Maxillary Sinus Carcinoma (6
)
Tongue Carcinoma (5
)
›
Associations
(57)
News
Trials
Search handles
@DrEzraCohen
@Dr_R_Kurzrock
@HeadNeckMD
@Jbauml
@LuisERaez1
@sueyom
Search handles
@DrEzraCohen
@Dr_R_Kurzrock
@HeadNeckMD
@Jbauml
@LuisERaez1
@sueyom
Filter by
Latest
10ms
Salivary gland neoplasm ma'am, myoepithelial cell rich, SUMP according to Milan system ma'am (@Venkateshgilly2)
10 months ago
12ms
The April NRG Currents #HeadandNeckCancerAwarenessMonth highlight is NRG-HN010 studying docetaxel + trastuzumab emtansine for recurrent, metastatic, or treatment-naive, unresectable HER2-positive #salivaryglandcancer - Read the article: https://t.co/wp9Q5nI5Ir @AlanHoMDPhD (@NRGonc)
12 months ago
Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
docetaxel • Kadcyla (ado-trastuzumab emtansine)
1year
Sharing our findings of TRPS1 in salivary gland tumors. Poster 98 - come and check it out! #ENTpath #USCAP2023 @UMiamiPathology (@JaylouVelez)
1 year ago
SKAP2 (Src Kinase Associated Phosphoprotein 2) • TRPS1 (Transcriptional Repressor GATA Binding 1)
1year
Great talk by @BinXu16 on mucoepidermoid carcinoma #ENTpath #USCAP23 #USCAP2023 (@menamansour)
1 year ago
SKAP2 (Src Kinase Associated Phosphoprotein 2)
1year
Her2 positive serous endometrial cancer and salivary gland cancer @NRGOncology #clinicaltrials now open to offer new therapeutic options for patients impacted by these cancers #NRG2023 @bicyclebritt @amandanfader (@JCohenMD)
1 year ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • NRG2 (Neuregulin 2)
|
HER-2 positive
over1year
HN010 is currently accruing! @StuartWongMD1 discusses the trial of docetaxel+tratuzumab vs ado-trastuzumab emtansine for recurrent, metastatic, or treatment-naive, unresectable #HER2+ #SalivaryGlandCancer on behalf of Study PI, Dr. Alan Ho https://t.co/PjNknIcDHg @MedicalCollege (@NRGonc)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
docetaxel • Kadcyla (ado-trastuzumab emtansine)
over1year
HN010 is currently accruing! @StuartWongMD1 discusses the trial of docetaxel+tratuzumab vs ado-trastuzumab emtansine for recurrent, metastatic, or treatment-naive, unresectable #HER2+ #SalivaryGlandCancer on behalf of Study PI, Dr. Alan Ho https://t.co/PjNknIcDHg @MedicalCollege (@NRGonc)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
docetaxel • Kadcyla (ado-trastuzumab emtansine)
over1year
NRG Currents Newsletter Featured Trial: Comparing Docetaxel and Trastuzumab to Ado-Trastuzumab Emtansine for HER2-positive Salivary Gland Cancer (NRG-HN010). Read more: https://t.co/i4rk9Zuuxf @AlanHoMDPhD @MSKCancerCenter (@NRGonc)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
docetaxel • Kadcyla (ado-trastuzumab emtansine)
over1year
Easy link to patient website for NRG-HN010! Click on: https://t.co/jBapwRCvv5 Molecular targeted therapy for recurrent and metastatic Her2+ salivary gland cancers #hncsm #salivaryglandcancer @hncalliance @spohnc_1 @NRGonc (@sueyom)
over 1 year ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
over1year
Today NRG-HN010 activated! We also launched our patient study webpage for this trial. Take a look and learn more from the FAQs, overviews, the patient brochure, and more at https://t.co/vHCVQ586Iz @AlanHoMDPhD @MSKCancerCenter #HeadandNeckCancer #SalivaryGlandCancer #HER2 (@NRGonc)
over 1 year ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
over1year
Protocol Activation! NRG-HN010: Docetaxel + Trastuzumab vs Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer. Read more: https://t.co/7YbYF9D3WU @AlanHoMDPhD @MSKCancerCenter @TheCTSU (@NRGonc)
over 1 year ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
docetaxel • Kadcyla (ado-trastuzumab emtansine)
over1year
NRG-HN010 "A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer" has been activated! @NRGonc @sueyom (@PTorresSaavedra)
over 1 year ago
Clinical • P2 data
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
docetaxel • Kadcyla (ado-trastuzumab emtansine)
over1year
You need better for Her2+ Salivary Duct Carcinoma as well. A lot of cancers need better (@kirumb)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
almost2years
Kudos for RAGNAR trial preliminary results: one of the largest histology agnostic basket trial! FGFR is a target in hard to treat cancer such as gliome, pancreas or salivary gland cancer @y_loriot @GustaveRoussy @MDAndersonNews (@drcmassard)
almost 2 years ago
Pan tumor
|
FGFR (Fibroblast Growth Factor Receptor)
almost2years
Awesome #HeadandNeckPath lecture by Dr. Michelle Williams @MDAndersonNews: p63 evaluation in salivary gland tumors and HPV/p16 testing for H&N tumors #oralpath #surgpath #pathology (@MTaherianMD)
almost 2 years ago
TP63 (Tumor protein 63)
almost2years
new NTRK publication today under the leadership of @LeXiuning @DavidHongMD @alexdrilon in salivary gland cancers thanks for including us in this team! @Bayer @NTRKers @ntrkconnectinfo @FLASCO_ORG @MCIStrong @mhshospital @OLACANCER1 @FLASCO_ORG https://t.co/uXZsoTKP3i (@LuisERaez1)
almost 2 years ago
Clinical
|
NTRK (Neurotrophic receptor tyrosine kinase)
2years
Dr. Oscar Lin @MSKPathology, et al. presents: A Multi-institutional Validation of a Modified Scheme for Subtyping Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) Monday, 3/21, 8:30-8:45AM #USCAP2022 #cytopathology #USCAP22 (@MSKPathology)
2 years ago
SKAP2 (Src Kinase Associated Phosphoprotein 2)
2years
Salivary duct carcinoma Her-2 and GATA 3?? (@sanatabish7)
2 years ago
HER-2 (Human epidermal growth factor receptor 2) • GATA3 (GATA binding protein 3)
over2years
🌀Androgen Receptor Pathway in Salivary Gland Cancer - a thoughtful #JCO editorial by @AlanHoMDPhD on this complex topic unraveling a highly heterogeneous disease #PrecisionOncology @ASCO_pubs #oncoalert @laura_locati @licitra_lisa https://t.co/7q3iUPamK6 (@elena_colombo_O)
over 2 years ago
AR (Androgen receptor)
over2years
NTRK gene fusions occur in an estimated 5% of cases of salivary gland tumors, including in approximately 80% of secretory carcinomas. https://t.co/KhsHUHQcIG (@TargetedOnc)
over 2 years ago
Clinical
|
NTRK (Neurotrophic receptor tyrosine kinase)
|
NTRK fusion
3years
@Jbauml hi Doctor, have you come across a patient with clear cell carcinoma of a salivary gland that has metastasized. And is PD-L1 negative interested in your thoughts if possible (@lambo1999)
3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
over3years
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: MyPathway, multiple basket study - Responsive matched disease includes Erbb2, braf, ptch1 aberrant and high TMB— each matched to the right drug. Annals of Oncology https://t.co/AYIunrgXCW (@Dr_R_Kurzrock)
over 3 years ago
Pan Tumor
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • PTCH1 (Patched 1)
|
TMB-H
over3years
Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer - Hanna - 2020 - Cancer - Modest activity https://t.co/Z7KTVYjNjn (@Dr_R_Kurzrock)
over 3 years ago
HRAS (Harvey rat sarcoma viral oncogene homolog)
|
HRAS mutation
|
Zarnestra (tipifarnib)
over3years
Tipifarnib has modest activity in HRAS mutated salivary gland cancers which brings up the question of combination targeting. https://t.co/FAnMTEAMGI (@DrEzraCohen)
over 3 years ago
HRAS (Harvey rat sarcoma viral oncogene homolog)
|
HRAS mutation
|
Zarnestra (tipifarnib)
almost4years
Congratulations to @HeadNeckMD, @AlanHoMDPhD, @DrEzraCohen and all of the co-authors for publication of their important paper “Tipifarnib in recurrent, metastatic HRAS‐mutant salivary gland cancer” in @JournalCancer! (@kuraoncology)
almost 4 years ago
HRAS (Harvey rat sarcoma viral oncogene homolog)
|
HRAS mutation
|
Zarnestra (tipifarnib)
almost4years
Our work showing clinical activity for #tipifarnib in #HRAS mutated #salivary gland cancers 🔍💊🧬🩺 @kuraoncology @AlanHoMDPhD @DrEzraCohen https://t.co/0A0qTJrjMm (@HeadNeckMD)
almost 4 years ago
Clinical
|
HRAS (Harvey rat sarcoma viral oncogene homolog)
|
HRAS mutation
|
Zarnestra (tipifarnib)
almost4years
Outcomes in HRAS mutated salivary gland cancers are disappointing relative to HNSCC. Unclear if comutation status or other variables prevented the type of responses we saw with HNSCC. #HNCSM #ASCO20 (@Jbauml)
almost 4 years ago
HRAS (Harvey rat sarcoma viral oncogene homolog)
|
HRAS mutation
almost4years
At #ASCO20, Dr Ho presented some data on tipifarnib in HRAS mutant cancers. This is an important potential target in oral cavity cancer and salivary gland cancers. These cancers are generally highly refractory to systemic therapies, and we need better treatments! #HNCSM #ASCO20 (@Jbauml)
almost 4 years ago
HRAS (Harvey rat sarcoma viral oncogene homolog)
|
HRAS mutation
|
Zarnestra (tipifarnib)
almost4years
Our updated @DanaFarber experience with adjuvant #HER2 therapy in high-risk #salivary cancers showing benefit among tumors with intense HER2 overexpression in @OncJournal 🧐🧬🩺 @SGCancerUK @SewantiLimaye @DanaFarberNews @DrEricWiner https://t.co/JLO3Nxv1iY (@HeadNeckMD)
almost 4 years ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login